Faeth Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Faeth Therapeutics, Inc. (FTH) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 39.37 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-04
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 7.95K shares, a 95.24% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-06-30 was -8.83K shares, a 102.89% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-03-31 was 11.98K shares, a 53.04% decline year-over-year.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 11.11K shares, a 97.86% decline from fiscal 2024.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 517.72K shares, a 28.81% increase from fiscal 2023.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 401.92K shares, a 34.14% decline from fiscal 2022.
- Faeth Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 610.29K shares, a 6.54% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 39.37K shares 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | 7.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 7.95K shares derived: sum of 2 quarters · filed 2026-03-30 | -879.00 shares derived: sum of 3 quarters · filed 2026-03-30 | 11.11K shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -8.83K shares derived: sum of 2 quarters · filed 2025-11-14 | 3.15K shares 10-Q · filed 2025-11-14 | 170.10K shares derived: sum of 4 quarters · filed 2025-11-14 |
| 2025-06-30 | -8.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 3.15K shares 10-Q · filed 2025-08-05 | 170.10K shares derived: sum of 3 quarters · filed 2025-08-05 | 190.32K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 11.98K shares 10-Q · filed 2025-05-06 | 178.93K shares derived: sum of 2 quarters · filed 2025-05-06 | 199.15K shares derived: sum of 3 quarters · filed 2025-05-06 | 504.19K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 166.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | 187.16K shares derived: sum of 2 quarters · filed 2025-03-28 | 492.20K shares derived: sum of 3 quarters · filed 2025-03-28 | 517.72K shares 10-K · filed 2025-03-28 |
| 2024-09-30 | 20.21K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 325.25K shares derived: sum of 2 quarters · filed 2024-11-14 | 350.77K shares 10-Q · filed 2024-11-14 | 355.40K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 305.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | 330.56K shares 10-Q · filed 2024-08-06 | 335.19K shares derived: sum of 3 quarters · filed 2024-08-06 | 335.19K shares derived: sum of 4 quarters · filed 2024-08-06 |
| 2024-03-31 | 25.52K shares 10-Q · filed 2024-05-09 | 30.15K shares derived: sum of 2 quarters · filed 2024-05-09 | 30.15K shares derived: sum of 3 quarters · filed 2024-05-09 | 397.71K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 4.63K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 4.63K shares derived: sum of 2 quarters · filed 2024-02-29 | 372.20K shares derived: sum of 3 quarters · filed 2024-02-29 | 401.92K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 367.57K shares derived: sum of 2 quarters · filed 2023-11-07 | 397.29K shares 10-Q · filed 2023-11-07 | 613.52K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 367.57K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 397.29K shares 10-Q · filed 2023-08-03 | 613.52K shares derived: sum of 3 quarters · filed 2023-08-03 | 621.06K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 29.72K shares 10-Q · filed 2023-05-09 | 245.96K shares derived: sum of 2 quarters · filed 2023-05-09 | 253.49K shares derived: sum of 3 quarters · filed 2023-05-09 | 433.21K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 216.24K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 223.77K shares derived: sum of 2 quarters · filed 2023-03-29 | 403.49K shares derived: sum of 3 quarters · filed 2023-03-29 | 610.29K shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 7.53K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 187.25K shares derived: sum of 2 quarters · filed 2022-11-08 | 394.05K shares 10-Q · filed 2022-11-08 | 743.95K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-06-30 | 179.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | 386.52K shares 10-Q · filed 2022-08-09 | 736.42K shares derived: sum of 3 quarters · filed 2023-03-29 | 777.01K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2022-03-31 | 206.80K shares 10-Q · filed 2022-05-10 | 556.70K shares derived: sum of 2 quarters · filed 2023-03-29 | 597.29K shares derived: sum of 3 quarters · filed 2023-03-29 | 816.03K shares derived: sum of 4 quarters · filed 2023-03-29 |
| 2021-12-31 | 349.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 390.49K shares derived: sum of 2 quarters · filed 2023-03-29 | 609.24K shares derived: sum of 3 quarters · filed 2023-03-29 | 652.98K shares 10-K · filed 2023-03-29 |
| 2021-09-30 | 40.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 259.33K shares derived: sum of 2 quarters · filed 2021-11-10 | 303.08K shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 218.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 262.50K shares 10-Q · filed 2021-08-11 | ||
| 2021-03-31 | 43.75K shares 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | 13.32K shares 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |